Femasys Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Femasys Inc. (NASDAQ: FEMY) announced that CEO Kathy Lee-Sepsick will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation will be available on-demand starting at 7:00 AM ET on September 12.

The conference will feature a fireside chat format, and Femasys management will hold one-on-one meetings during the event. Femasys focuses on developing minimally invasive technologies for reproductive health, including FemBloc® for birth control and FemaSeed® for infertility.

ATLANTA, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Kathy Lee-Sepsick, founder, president & chief executive officer, will present virtually at the H.C. Wainwright 24^th Annual Global Investment Conference being held on a hybrid basis September 12-14, 2022, and in-person at the Lotte New York Palace Hotel in New York, NY.

H.C. Wainwright 24^th Annual Global Investment Conference

Date:	Monday, September 12, 2022
Format:	Fireside chat
Time:	Available on-demand starting at 7:00 AM ET

The Femasys management team will also participate in one-on-one meetings during the event. Interested investors should contact their H.C. Wainwright representative.

About Femasys

Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc^® permanent birth control and FemaSeed^® localized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound, FemVue^®, is currently marketed in the United States. Femasys is also advancing FemCath^™, an intrauterine catheter for selective evaluation of the fallopian tubes and FemCerv^®, an endocervical tissue sampler that is the first product of the technology platform for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting. To learn more, visit www.femasys.com or follow us on Twitter and LinkedIn.

Contacts:

Investors
Chuck Padala
LifeSci Advisors, LLC
+1-917-741-7792
chuck@lifesciadvisors.com

Media
Karissa Cross, Ph.D.
LifeSci Communications
kcross@lifescicomms.com

Femasys Inc.
Investor Contact:
IR@femasys.com 

Media Contact:
Media@femasys.com 

FAQ

What is the date of Femasys' presentation at the H.C. Wainwright conference?

Femasys will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022.

What is the format of Femasys' presentation at the conference?

The presentation will be in a fireside chat format, available on-demand starting at 7:00 AM ET on September 12, 2022.

Who is presenting on behalf of Femasys at the conference?

Kathy Lee-Sepsick, the CEO of Femasys Inc., will present at the conference.

What are Femasys' key products mentioned in the press release?

Femasys' key products include FemBloc® for permanent birth control and FemaSeed® for localized directional insemination.

How can investors schedule one-on-one meetings with Femasys during the conference?

Interested investors should contact their H.C. Wainwright representative to schedule one-on-one meetings.